Printer Friendly

ATRIX LABORATORIES COMMENCES CLINICAL STUDIES ON PERIODONTAL PRODUCTS

ATRIX LABORATORIES COMMENCES CLINICAL STUDIES ON PERIODONTAL PRODUCTS
 FORT COLLINS, Colo., Sept. 22 /PRNewswire/ -- Atrix Laboratories, Inc. (NASDAQ: ATRX), today announced that it has begun a new round of clinical studies on its two periodontal products, the Perio Product and the guided tissue regeneration product, Atrisorb(TM).
 The Perio Product utilizes Atrix's proprietary drug delivery system, Atrigel(TM). This product is being re-evaluated in a clinical study designed to clarify certain issues that arose from Phase III clinical trials completed earlier this year on patients with chronic adult periodontitis.
 The study is being conducted in five centers around the country and will include the use of sanguinarine, Atrix's proprietary anti-microbial agent, and doxycycline, an FDA approved antibiotic agent.
 Atrix has simultaneously commenced its first human clinical studies on Atrisorb, its guided tissue regeneration membrane. This test is a four-center study, and its purpose is to demonstrate the efficacy of Atrisorb in aiding tissue re-attachment after gum flap surgery.
 Dr. G. Lee Southard, president and CEO, stated: "This is an extremely exciting time for Atrix. It is the first time in the company's history that we have two periodontal products in clinical trials at the same time. The pre-clinical test results on both the Perio and Atrisorb products have been very encouraging. We feel confident that an effective treatment for chronic adult periodontal disease will result from the Perio Product trials and that the Atrisorb trials will lead to new and improved ways to enhance guided tissue regeneration."
 Atrix Laboratories is a drug delivery company with a unique, proprietary drug delivery technology that is biodegradable and can be utilized for a broad range of human and animal applications, including the treatment of periodontal disease.
 -0- 9/22/92
 /CONTACT: G. Lee Southard, Ph.D., president and CEO of Atrix, 303-482-5868; or Susan Sherman of Cameron Associates, 212-644-9560, for Atrix/
 (ATRX) CO: Atrix Laboratories, Inc. ST: Colorado IN: MTC SU:


GK-PS -- NY007 -- 1999 09/22/92 08:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1992
Words:327
Previous Article:HOWARD JOHNSON OFFERS UP TO $54 MILLION IN TRAVEL DISCOUNTS THROUGH STAY AND SAVE! FALL MARKETING CAMPAIGN
Next Article:BEST BUY CO., INC. REPORTS RESULTS FOR SECOND QUARTER 1993
Topics:


Related Articles
ATRIX LABORATORIES REPORTS RESULTS OF LIMITED PARTNERS MEETING
ATRIX LABORATORIES ANNOUNCES REVISION TO COLGATE CONTRACT
ATRIX LABORATORIES RECEIVES FDA CLEARANCE FOR FIRST PRODUCT
ATRIX LABORATORIES COMPLETES PHASE III CLINICAL TRIALS
Atrix Laboratories Announces Successful Clinical Trial Results for Innovative Treatment of Periodontal Disease
Block Drug Company And Atrix Laboratories Sign Corporate Alliance Agreement
Block Drug Corporation to Market Atridox(TM) Periodontal Therapy in Canada
Atrix Laboratories Reports 1997 Third Quarter and Nine Month Financial Results
Atrix Laboratories Reports 1997 Fourth Quarter and Year-End Financial Results
Atrix Laboratories Begins Shipments of Atridox; Earns $5 Million Milestone Payment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters